Ara-290 10mg x 10 Vials
$42.23$46.93 (-10%)
Ara 290 10 mg: ARA-290, also known as Cibinetide, is a synthetic peptide associated with an erythropoietin-derived structural motif. It is a distinct peptide reference rather than the full erythropoietin protein. The shorter designed structure provides a separate analytical target. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.
Ara 290 10 mg Australia
Ara 290 10 mg is listed at AU Peptides Shop in a vial presentation. This page brings together the compound identity, reference chemistry and laboratory considerations relevant to this specific catalogue entry. It is intended exclusively for controlled in vitro laboratory research, not personal use.
Product description
ARA-290, also known as Cibinetide, is a synthetic peptide associated with an erythropoietin-derived structural motif. It is a distinct peptide reference rather than the full erythropoietin protein. The shorter designed structure provides a separate analytical target.
ARA-290 and EPO should not be represented as the same chemical material. A product amount stated in milligrams also should not be converted into biological activity units without a documented substance-specific standard.
Chemical information and molecular structure
| Reference designation | ARA-290 |
|---|---|
| Selected reference species | Cibinetide |
| Reference molecular formula | C51H84N16O21 |
| Reference molecular weight | 1257.3 g/mol |
| Reference identifier | PubChem CID 91810664 |
| Sequence information | Confirm the complete sequence, terminal groups and relevant modifications in the product documents. |
View the reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied Ara 290 10 mg.
Reference formula and molecular weight depend on the represented chemical species. Counterions, hydration, oxidation state, terminal modifications and formulation ingredients can change the relationship between a database molecule and the supplied material. Use the named reference species for structural comparison, and use the batch specification for the actual product composition.
Research applications and experimental scope
- Identity assessment of an erythropoietin-related peptide.
- Controlled receptor-associated experimental systems.
- Peptide mapping and degradation profiling.
- Comparison with larger parent-protein references.
These are laboratory research topics and analytical objectives, not claims that the supplied product has achieved a biological result. Define the experimental question, model and acceptance criteria before comparing materials. A literature observation made with a different sequence, formulation or model cannot establish the performance of this catalogue item.
Analytical characterisation
For ARA-290, sequence-sensitive identification and chromatographic profiling answer different questions. A compatible intact mass supports a molecular comparison, while a suitable mapping or fragmentation method may provide additional sequence evidence. A chromatographic peak area alone does not confirm every residue, terminal group or stereochemical feature.
Use reference material that matches the sequence and modifications being evaluated. Separate the identification question from the measurement of impurities, water, counterions or peptide content. A single percentage should retain the method and reporting basis under which it was obtained; it should not be expanded into an unsupported claim about sterility, activity or total material composition.
Laboratory model and control considerations
An in vitro experiment with ARA-290 should distinguish the test-material response from effects of the vehicle, assay matrix and any additional ingredients. Include the controls appropriate to the study design, and keep the reference standard and test sample traceable to their own preparation records. Where a readout depends on cell viability or matrix composition, assess those factors independently of the primary measurement.
Record the sample identity, selected product option, preparation history and analytical method used for the comparison. Repeatability within one run does not by itself establish specificity or transferability to another model. Report observations within the limits of the experimental system rather than treating an in vitro result as evidence of a clinical benefit.
Supplied format and product specifications
| Product name | Ara 290 10 mg |
|---|---|
| Catalogue format | vial presentation |
| Quantity wording in listing | 10 mg |
| Purity / certification | Refer to the relevant batch report; no percentage or certification is assigned without product documentation. |
A vial describes packaging, not proof of lyophilisation or a particular solution composition. Where the supplied material is documented as a lyophilized powder, preserve that description and its batch-specific handling requirements. A mass in a title does not establish final solution volume, concentration or solvent compatibility.
Solubility and matrix compatibility
For ARA-290, use product-specific solubility information and a laboratory method appropriate to the selected presentation. Apparent dispersion is not necessarily complete dissolution, and a visually clear preparation does not establish chemical stability. Assess recovery and matrix compatibility using the measurement required for your experiment.
Where the product contains additional ingredients, distinguish dissolution of the reference compound from extraction of the finished formulation. Record the documented matrix and any observed interference so another analyst can interpret the result. No universal solvent, solubility limit or preparation protocol is assigned from this catalogue name.
Storage and handling
Use the storage conditions specified for the supplied Ara 290 10 mg batch and presentation. A universal freezer temperature, refrigeration interval or prepared-sample expiry is not assigned from the compound name alone. Obtain the relevant product guidance when storage or sample stability is an acceptance criterion for your work.
Maintain traceable labels and document the handling history relevant to the study. Assess changes in appearance, analytical profile or recovery against a validated method rather than assuming that an unchanged label establishes stability. Aseptic laboratory technique does not by itself demonstrate that a research product is sterile; sterility and related quality attributes require their own evidence.
Australian research enquiries
For Ara 290 10 mg in Australia, include the complete listing name, required option and any analytical documentation requirements when you contact AU Peptides Shop. Browse the research catalogue for other individually specified materials. Current purchasing options show price and availability; batch evidence should be reviewed separately.
Scientific references
- PubChem reference: Cibinetide
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Research compliance notice
For controlled in vitro laboratory research only. Not for human or veterinary use. This description provides scientific reference information and does not recommend dosing, administration or treatment. Research-use labelling does not establish regulatory approval or permission for a particular activity under Australian therapeutic-goods requirements.
